Research institution
Ruijin Hospital Clinical Trials
Studies where Ruijin Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 321Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Recurrent Ascending Cholangitis After Biliary-enteric Anastomosis
Rifaximin for Prevention of Recurrent Mild-to-moderate Ascending Cholangitis After Biliary-enteric Anastomosis
This single-center prospective randomized controlled trial plans to recruit 60 adult patients with recurrent ascending cholangitis after biliary-enteric anastomosis.
- Trial name
- NCT07895433
- Testing
- Rifaximin combined with standard care, Standard Care (in control arm)
- Volunteers
- 60 people
- Sponsor
- Ruijin Hospital
Primary IgA Nephropathy
Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions
The goal of this clinical trial is to evaluate if obinutuzumab beta works to treat primary IgA nephropathy with active proliferative lesions in adults. It will also learn about the safety of obinutuzumab beta.
- Trial name
- NCT07888335
- Testing
- Obinutuzumab Beta
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma
Urinary Cell-Free DNA Liquid Biopsy for Urothelial Cancer Diagnosis and Origin Identification
Urothelial carcinoma is the most common cancer of the urinary system. It includes bladder cancer and upper urinary tract cancer, which starts in the kidney pelvis or ureter.
- Conditions
- Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT07888374
- Where
- China
- Volunteers
- 477 people
- Sponsor
- Ruijin Hospital
Esophageal Cancer
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer
This study evaluates the safety, efficacy, and health economic outcomes of modular robotic-assisted minimally invasive esophagectomy (RAMIE) compared with conventional thoracoscopic minimally invasive esophagectomy (MIE) in…
- Trial name
- mRAMIE2026 (NCT07888140)
- Testing
- Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Ruijin Hospital
Poor Graft Function, Myelodysplastic Syndromes
Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT
Preclinical evidence indicates that IL-1 inflammatory signaling suppresses bone marrow mesenchymal stromal cells (MSCs) from secreting stem cell factor (SCF), leading to failure of their hematopoietic supportive capacity, and…
- Conditions
- Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07888348
- Testing
- Anakinra
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ruijin Hospital
Lung Neoplasm Malignant
Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC
Neoadjuvant immunotherapy combined with chemotherapy followed by surgery has become an important treatment strategy for resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT07890636
- Testing
- Adebrelimab, Adjuvant treatment
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Ruijin Hospital
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Coronary Artery Bypass, Radial Artery Grafts
Fasciotomy and Predilation for Radial Artery Grafts in CABG
The goal of this clinical trial is to learn if a new way to prepare a radial artery graft during coronary artery bypass grafting (CABG) can improve outcomes for adults having this surgery.
- Trial name
- RAPID-CABG (NCT07868692)
- Testing
- Radial Artery Harvesting With Fasciotomy and Predilation, Radial Artery Harvesting Without Fasciotomy or Predilation
- Where
- China
- Volunteers
- 314 people
- Sponsor
- Ruijin Hospital
Myeloid Neoplasms With Myelofibrosis
An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to…
- Trial name
- JAK-PeriMF (NCT07883382)
- Testing
- gecacitinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Completed, with results posted
All 5Gastric Cancer, Chemotherapy Effect
Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer
Safety and efficacy study of neoadjuvant chemotherapy (FLOT versus SOX) for gastric cancer patients in high volume center of China
- Trial name
- NCT03636893
- Testing
- FLOT Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Healthy
A Tolerance Clinical Study on Aerosol Inhalation of Mesenchymal Stem Cells Exosomes In Healthy Volunteers
Exosomes are naturally occurring nanosized vesicles and comprised of natural lipid bilayers with the abundance of adhesive proteins that readily interact with cellular membranes.
- Trial name
- NCT04313647
- Testing
- 1X level of MSCs-Exo, 2X level of MSCs-Exo, 4X level of MSCs-Exo
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy, Tractional Retinal Detachment
Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.
- Trial name
- NCT02816710
- Testing
- Conbercept
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Coronary Artery Bypass, Antiplatelet Agents
Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery
The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1…
- Trial name
- DACAB (NCT02201771)
- Testing
- Aspirin, Ticagrelor
- Where
- 6 sites in China
- Volunteers
- 500 people
- Sponsor
- Ruijin Hospital
Anesthesia
Anesthesia and Lymphocytes Apoptosis
Most researches revealed that volatile anesthetic sevoflurane has a more marked cardioprotective effect against ischemia compared with intravenous agent propofol.However, propofol has been suggested to be more benefit for…
- Trial name
- OPCAB (NCT01461551)
- Testing
- Sevoflurane, Propofol, combine of sevoflurane and propofol
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Ruijin Hospital